OrbusNeich has announced the appointment of B Wayne Johnson as president and chief executive officer, with responsibility for all commercial and clinical aspects of the company. Johnson, who has more than 32 years of medical device experience, will continue placing a heavy emphasis on research and development, cementing OrbusNeich’s reputation as an innovative, forward-looking leader in interventional cardiology.
“We are a leader in terms of R&D, and we intend to keep our focus on developing new and better ways to help interventional cardiologists provide the best possible care for their patients,” says Johnson. “In an industry that is now heavily driven by design modification, we seek to develop ground-breaking products, such as our Combo dual therapy stent. I take this responsibility seriously and look forward to keeping OrbusNeich on its innovative path.”
Under Johnson’s leadership, OrbusNeich will expand its product portfolio and continue to build on the success of its balloon business and on the launch of the Combo dual therapy stent.
“We face the same global challenges as any company in this business,” says Johnson. “For a company our size we have an impressive array of innovative accomplishments. For this I am extremely proud of my colleagues at OrbusNeich. We strongly believe the best strategy for competing in our field is to continue to innovate in order to offer physicians and patients the most effective and safest products available.”
Johnson joined OrbusNeich in 2002 and most recently has served in the role of president and chief operating officer. Prior to joining OrbusNeich, Johnson was president and chief executive officer of Sutura, a development-stage company based in Fountain Valley, California, USA, focused on commercialising suture-mediated wound closure products. Before Sutura, he was president and chief executive officer of Prostec LLC (a division of Syntheon LLC), dedicated to devices for prostate brachytherapy. Prior to this, he spent 18 years with Cordis, holding roles of increasing responsibility, including vice president and general manager of the company’s largest facility. He was also a member of the Cordis operating board as vice president of worldwide operations.
Since 2012 he has been a member of the board of directors of Microvisk Technologies, a UK-based company developing medical diagnostic devices. He holds a BS in biology and both an MBA and an MS degree in management from Rensselaer Polytechnic Institute.
